Page 187 - Read Online

Neumann et al. J Cancer Metastasis Treat 2018;4:13 I http://dx.doi.org/10.20517/2394-4722.2017.60 Page 7 of 7

20. Koeppen M, Eckle T, Eltzschig HK. Interplay of hypoxia and A2B adenosine receptors in tissue protection. Adv Pharmacol 2011;61:145-
86.
21. Cronstein BN, Daguma L, Nichols D, Hutchison AJ, Williams M. The adenosine/neutrophil paradox resolved: human neutrophils possess
both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. J Clin Invest 1990;85:1150-7.
22. Novitskiy SV, Ryzhov S, Zaynagetdinov R, Goldstein AE, Huang Y, Tikhomirov OY, Blackburn MR, Biaggioni I, Carbone DP, Feoktistov I,
Dikov MM. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood 2008;112:1822-31.
23. Lukashev D, Sitkovsky M, Ohta A. From “Hellstrom Paradox” to anti-adenosinergic cancer immunotherapy. Purinergic Signal
2007;3:129-34.
24. Ehrentraut H, Westrich JA, Eltzschig HK, Clambey ET. Adora2b adenosine receptor engagement enhances regulatory T cell abundance
during endotoxin-induced pulmonary inflammation. PLoS One 2012;7:e32416.
25. Ohta A. A metabolic immune checkpoint: adenosine in tumor microenvironment. Front Immunol 2016;7:109.
26. Iannone R, Miele L, Maiolino P, Pinto A, Morello S. Blockade of A2b adenosine receptor reduces tumor growth and immune suppression
mediated by myeloid-derived suppressor cells in a mouse model of melanoma. Neoplasia 2013;15:1400-9.
27. Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, Huang Q, Liu J, Takeda K, Teng MWL, Sachsenmeier K, Smyth MJ. Co-
inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell 2016;30:391-403.
28. Leone RD, Lo YC, Powell JD. A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy. Comput Struct
Biotechnol J 2015;13:265-72.
29. Sorrentino C, Miele L, Porta A, Pinto A, Morello S. Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12
expression in FAP-positive tumor stromal cells, enhancing tumor progression. Oncotarget 2016;7:64274-88.
30. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari
G, Bashashati A, Russell R, McKinney S, Group M, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz
F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S. The genomic and transcriptomic
architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486:346-52.
31. Alluri P, Newman LA. Basal-like and triple-negative breast cancers: searching for positives among many negatives. Surg Oncol Clin N
Am 2014;23:567-77.
32. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O,
Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast
tumours. Nature 2000;406:747-52.
33. Loi S, Pommey S, Haibe-Kains B, Beavis PA, Darcy PK, Smyth MJ, Stagg J. CD73 promotes anthracycline resistance and poor prognosis
in triple negative breast cancer. Proc Natl Acad Sci U S A 2013;110:11091-6.
34. Buisseret L, Pommey S, Allard B, Garaud S, Bergeron M, Cousineau I, Ameye L, Bareche Y, Paesmans M, Crown JPA, Di Leo A, Loi
S, Piccart-Gebhart M, Willard-Gallo K, Sotiriou C, Stagg J. Clinical significance of CD73 in triple-negative breast cancer: multiplex
analysis of a phase III clinical trial. Ann Oncol 2017; doi: 10.1093/annonc/mdx730.
35. Taylor NA, Vick SC, Iglesia MD, Brickey WJ, Midkiff BR, McKinnon KP, Reisdorf S, Anders CK, Carey LA, Parker JS, Perou CM,
Vincent BG, Serody JS. Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. J Clin Invest 2017;127:3472-83.
36. Panjehpour M, Castro M, Klotz KN. Human breast cancer cell line MDA-MB-231 expresses endogenous A2B adenosine receptors
mediating a Ca2+ signal. Br J Pharmacol 2005;145:211-8.
37. Fernandez-Gallardo M, Gonzalez-Ramirez R, Sandoval A, Felix R, Monjaraz E. Adenosine stimulate proliferation and migration in triple
negative breast cancer cells. PLoS One 2016;11:e0167445.
38. Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, Dwyer KM, Smyth MJ. Anti-CD73 antibody therapy inhibits
breast tumor growth and metastasis. Proc Natl Acad Sci U S A 2010;107:1547-52.
39. Mittal D, Sinha D, Barkauskas D, Young A, Kalimutho M, Stannard K, Caramia F, Haibe-Kains B, Stagg J, Khanna KK, Loi S, Smyth
MJ. Adenosine 2B receptor expression on cancer cells promotes metastasis. Cancer Res 2016;76:4372-82.
40. Desmet CJ, Gallenne T, Prieur A, Reyal F, Visser NL, Wittner BS, Smit MA, Geiger TR, Laoukili J, Iskit S, Rodenko B, Zwart W, Evers
B, Horlings H, Ajouaou A, Zevenhoven J, van Vliet M, Ramaswamy S, Wessels LF, Peeper DS. Identification of a pharmacologically
tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci U S A 2013;110:5139-44.
41. Bernardi R, Gianni L. Hallmarks of triple negative breast cancer emerging at last? Cell Res 2014;24:904-5.
42. Pusztai L, Silber A, Hofstatter EW, Chung GG, Horowitz NR, Lannin DR, Killelea BK, Chagpar AB, Szekely B, Frederick C, Rispoli
L, DiGiovanna M. Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense
doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): a phase I/II
trial. J Clin Oncol 2017;35 Suppl 15:abstr572.